Respiratory complications of Parkinson's disease

Seminars in Respiratory and Critical Care Medicine

Volumn 23, Issue 3, 2002, Pages 261-265

  Shill, Holly ^a   Stacy, Mark ^a  

^a Muhammad Ali Parkinson Res Center   (United States)

Author keywords

Chest wall rigidity; Dopaminergic; Levodopa; Parkinson's disease; Pulmonary complications

Indexed keywords

ERGOT DERIVATIVE; LEVODOPA;

DOPAMINERGIC NERVE CELL; HUMAN; HYPERKINESIA; LUNG COMPLICATION; LUNG FIBROSIS; LUNG VENTILATION; PARKINSON DISEASE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; THORAX WALL; UPPER RESPIRATORY TRACT OBSTRUCTION;

EID: 0036062014     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-33034     Document Type: Review

References (43)

1. Parkinsonism: Onset, progression and mortality
2. Akinesia in Parkinson's disease
3. Thyroarytenoid muscle activity associated with hypophonia in Parkinson disease and aging
4. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor
5. Posteroventral medial pallidotomy in Parkinson's disease
6. Treatment of Parkinson hypophonia with percutaneous collagen augmentation
7. Pulmonary function in Parkinson's disease
8. Defective motor control of coughing in Parkinson's disease
9. Involvement of upper-airway muscles in extrapyramidal disorders: A cause of airflow limitation
10. Obstructive respiratory dysfunction in parkinsonian patients
11. Airway dysfunction in patients with Parkinson's disease
12. Obstructive and restrictive pulmonary dysfunctions in Parkinson's disease
13. Effects of treatment on airway dynamics and respiratory muscle strength in Parkinson's disease
14. Effects of levodopa on pulmonary function in Parkinson's disease
15. Stridor and parkinsonism
16. Acute respiratory failure during drug manipulation in patients with Parkinson's disease
17. Acute respiratory failure from dopamine agonist withdrawal
18. Upper airway involvement in Parkinson's disease resulting in postoperative respiratory failure
19. Perioperative problems in Parkinson's disease and their management: Apomorphine with rectal domperidone
20. Dyspnea as a symptom in Parkinson's syndrome
21. Some "minor" aspects of parkinsonism, especially pulmonary function
22. Levodopa dosage and ventilatory function in Parkinson's disease
23. Respiratory-muscle involvement in Parkinson's disease
24. Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson's disease
25. Respiration and sleep in Parkinson's disease
26. Stridor and death in multiple system atrophy
27. Pathophysiological findings in a patient with Shy-Drager and alveolar hypoventilation syndromes
28. Respiratory dyskinesias: Extrapyramidal dysfunction and dyspnea
29. Respiratory dysfunction due to L-dopa therapy for parkinsonism: Diagnosis using serial pulmonary function tests and respiratory inductive plethysmography
30. Stridor during dystonia phases of Parkinson's disease
31. "Panic attacks" in Parkinson's disease: A long-term complication of levodopa therapy
32. Pharmacotherapy for advanced Parkinson's disease
33. Pleuropulmonary disease associated with dopamine agonist therapy
34. Cabergoline in Parkinson's disease complicated by motor fluctuations
35. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease
36. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease
37. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease
38. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos
39. Parkinson's disease: An investigation of exercise capacity, respiratory function, and gait
40. The effects of a pulmonary rehabilitation program on pulmonary function tests and exercise tolerance in patients with Parkinson's disease
41. Respiratory muscle dysfunction in Parkinson's disease